SAN
JOSE, Calif., Feb. 14,
2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa"
or the "Company") (NASDAQ: ANIX), a biotechnology company focused
on the treatment and prevention of cancer, today announced that its
Chairman and CEO, Dr. Amit Kumar,
was featured in an interview with Alpha Wolf Trading. In the
discussion, Dr. Kumar provided insights into Anixa's groundbreaking
CAR-T cell therapy for ovarian cancer and its breast cancer vaccine
program, highlighting the Company's innovative approach to
immunotherapy and cancer prevention.
During the interview, Dr. Kumar provided key insights into
Anixa's CAR-T cell therapy, which is designed to harness the power
of the immune system to target ovarian cancer cells. Unlike
traditional CAR-T therapies that have been successful in blood
cancers, Anixa's approach aims to overcome the challenges of
treating solid tumors, representing a major advancement in
immunotherapy.
Dr. Kumar also discussed Anixa's breast cancer vaccine program,
which is designed to prevent triple-negative breast cancer
(TNBC)—the most aggressive and hardest-to-treat form of breast
cancer. Currently in clinical trials, this vaccine has the
potential to be a game-changer in breast cancer prevention.
A key strength of Anixa's business model is its capital
efficiency and low burn rate, enabled by its strategic partnerships
with world-renowned research institutions. By leveraging
collaborations with its partners, Anixa minimizes the need for
large in-house R&D expenditures, ensuring that its financial
resources are allocated efficiently.
"Our partnership-driven approach allows us to advance
cutting-edge therapies while maintaining a low burn rate," said Dr.
Kumar. "By working with top-tier institutions, we maximize the
impact of our funding and accelerate the development of novel
cancer treatments without the heavy financial burden typically
associated with biotech companies."
To watch Dr. Amit Kumar's full
interview on Alpha Wolf Trading, please visit:
https://www.youtube.com/watch?v=sk7MonYXcH0.
About Anixa Biosciences, Inc.
Anixa is a
clinical-stage biotechnology company focused on the treatment and
prevention of cancer. Anixa's therapeutic portfolio consists of an
ovarian cancer immunotherapy program being developed in
collaboration with Moffitt Cancer Center, which uses a novel type
of CAR-T, known as chimeric endocrine receptor-T cell (CER-T)
technology. The Company's vaccine portfolio includes vaccines being
developed in collaboration with Cleveland Clinic to treat and
prevent breast cancer and ovarian cancer, as well as additional
cancer vaccines to address many intractable cancers, including high
incidence malignancies in lung, colon, and prostate. These vaccine
technologies focus on immunizing against "retired" proteins that
have been found to be expressed in certain forms of cancer. Anixa's
business model of partnering with world-renowned research
institutions on all stages of development allows the Company to
continually examine emerging technologies in complementary fields
for further development and commercialization. To learn more, visit
www.anixa.com or follow Anixa on Twitter, LinkedIn, Facebook
and YouTube.
Forward-Looking Statements
Statements that are not historical fact may be considered
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements are not statements of historical facts, but rather
reflect Anixa's current expectations concerning future events and
results. We generally use the words "believes," "expects,"
"intends," "plans," "anticipates," "likely," "will" and similar
expressions to identify forward-looking statements. Such
forward-looking statements, including those concerning our
expectations, involve risks, uncertainties and other factors, some
of which are beyond our control, which may cause our actual
results, performance or achievements, or industry results, to be
materially different from any future results, performance, or
achievements expressed or implied by such forward-looking
statements. These risks, uncertainties and factors include, but are
not limited to, those factors set forth in "Item 1A - Risk Factors"
and other sections of our most recent Annual Report on Form 10-K as
well as in our Quarterly Reports on Form 10-Q and Current Reports
on Form 8-K. We undertake no obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by law.
You are cautioned not to unduly rely on such forward-looking
statements when evaluating the information presented in this press
release.
Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download
multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-chairman-and-ceo-discusses-pioneering-car-t-cell-therapy-and-breast-cancer-vaccine-in-alpha-wolf-trading-interview-302376833.html
SOURCE Anixa Biosciences, Inc.
